OncomiRs miR-106a and miR-17 negatively regulate the nucleoside-derived drug transporter hCNT1.

ABSTRACT: High-affinity uptake of natural nucleosides as well as nucleoside derivatives used in anticancer therapies is mediated by human concentrative nucleoside transporters (hCNTs). hCNT1, the hCNT family member that specifically transports pyrimidines, is also a transceptor involved in tumor progression. In particular, oncogenesis appears to be associated with hCNT1 downregulation in some cancers, although the underlying mechanisms are largely unknown. Here, we sought to address changes in colorectal and pancreatic ductal adenocarcinoma-both of which are important digestive cancers-in the context of treatment with fluoropyrimidine derivatives. An analysis of cancer samples and matching non-tumoral adjacent tissues revealed downregulation of hCNT1 protein in both types of tumor. Further explorati

SUBMITTER: Boces-Pascual C 

PROVIDER: S-EPMC8629896 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature